Vivaldi, a Genzyme Veteran who has been with the company since 1997, worked his way up the ranks to his previous role as president of the renal and endocrinology business.
In his appointment to the management team, he is joined by William Sibold, who will become the company's head of multiple sclerosis.
A spokesperson for the firm said: “The MS and Rare Disease businesses constitute Genzyme's core focus following its integration with Sanofi.”
“Our goal is to build a world-leading multiple sclerosis franchise,” added David Meeker.
William Sibold, head of multiple sclerosis at Genzyme Rogério Vivaldi, head of rare diseases at Genzyme Jonathan Arnold, VP and general manager of sterile technologies for Catalent Ken DePinto, MTI's VP of strategic services John Clarke, new non-executive chairman at Futura Medical Kristina Bloomquist, executive director of the Medical Research Institute